Refractory Anemia With Excess Blasts In Transformation
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
TET2,
FANCB,
CD34,
RUNX1,
CCR7,
MECOM,
KMT2A,
EPO,
GATA2,
HPSE2,
ACSL5,
SF3B1,
ACSL6,
AKAP12,
DLK1,
CIP2A,
IGHV1-12,
ACHE,
NSD1,
VEGFA,
DERL1,
ATAD1,
ASXL1,
ILDR1,
MIR29B1,
MIR29B2,
VIM2P,
MOGS,
SRSF2,
U2AF1
TET2,
FANCB,
CD34,
RUNX1,
CCR7,
MECOM,
KMT2A,
EPO,
GATA2,
HPSE2,
ACSL5,
SF3B1,
ACSL6,
AKAP12,
DLK1,
CIP2A,
IGHV1-12,
ACHE,
NSD1,
VEGFA,
DERL1,
ATAD1,
ASXL1,
ILDR1,
MIR29B1,
MIR29B2,
VIM2P,
MOGS,
SRSF2,
U2AF1,
THY1,
BCL2,
BCR,
CBL,
CDKN2B,
CHEK1,
CSF3,
ETV6,
FLT3,
HLA-DRB1,
ITGA2B,
MCL1,
NCAM1,
NRAS,
RARS1,
BCHE,
SPN,
THPO,
U2AF1L5
Drugs
2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one,
Allogeneic ex vivo expanded umbilical cord blood cells,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus
2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one,
Allogeneic ex vivo expanded umbilical cord blood cells,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Arsenic trioxide
(
Arsenic Trioxide Accord,
Arsenic trioxide Mylan,
Arsenic trioxide medac,
TRISENOX
),
Asunercept,
Azacitidine
(
AZACITIDINE ACCORD,
AZACITIDINE BETAPHARM,
AZACITIDINE CELGENE,
AZACITIDINE MYLAN,
VIDAZA
),
Decitabine
(
DACOGEN
),
Fully human IgG1 antibody specific for CD33,
Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2,
Imatinib mesilate
(
GLEEVEC,
GLIVEC,
IMATINIB TEVA,
IMATINIB TEVA B.V.
),
Lenalidomide
(
LENALIDOMIDE ACCORD,
REVLIMID
),
Lintuzumab,
Luspatercept
(
REBLOZYL
),
Magrolimab,
Mocetinostat,
NEDD8-activating enzyme (NAE) inhibitor,
Rigosertib,
Sapacitabine,
Sotatercept,
Stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,
Thalidomide
(
THALIDOMIDE CELGENE,
THALOMID
),
Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3),
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
A rare hematologic disease characterized by the presence of 20-29% blasts in the bone marrow, presence of 5-29% blasts in the peripheral blood, and/or presence of Auer rods. Patients show relatively stable peripheral blood counts for weeks or months, with specific cytogenetic and molecular genetic characteristics constituting important prognostic factors.